Full Text View
Tabular View
Study Results
Related Studies
15 mg Mirtazapine Orally Disintegrating Tablets, Fasting
This study has been completed.
Study NCT00835575   Information provided by Teva Pharmaceuticals USA

First Received on January 30, 2009.   Last Updated on September 1, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Healthy
Additional drug interventions recognized in this trial
Mianserin
Mirtazapine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents, Tricyclic
Central Nervous System Agents
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Therapeutic Uses
Sponsors listed in this trial
Teva Pharmaceuticals USA


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services